Investigational Peanut Vaccine Study Drug Research Study

What
We want to learn more about the safety and tolerability of an investigational peanut vaccine study drug for adults with non-severe peanut allergies. We want to see if the peanut vaccine study drug will train the immune system not to have an allergic reaction when the body comes in contact with peanut proteins.

Who
Adults, 18 to 55 years old, with a physician-diagnosed, non-severe peanut allergy or a history of peanut allergy, may be eligible to participate.

What’s Involved
The study has up to 13 visits over a period of 8 1/2 months. Participants will have 6 weeks of study drug treatment (and receive either 4 doses of vaccine study drug or placebo, which contains no active ingredient) and 6 months of follow-up.

Pay
Participants will receive up to $1300 for their time and travel.

Contact
Xxxxxx Xxxxxxxx | xxxxx.xxxxxxxx@cchmc.org | XXX-XXX-XXXX